Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02714920
Other study ID # 69HCL15_0188
Secondary ID 2015-A00911-48
Status Completed
Phase N/A
First received
Last updated
Start date May 2016
Est. completion date November 23, 2020

Study information

Verified date December 2021
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Squamous cell carcinoma (HNSCC) is the most frequent form of head and neck cancer. The therapeutic choice depends on the stage of the disease and the habits of the medical teams. Surgery, radiotherapy and chemotherapy can be used, alone or combined. However, none of the existing strategies has proven its superiority. Chemotherapy and radiotherapy induce DNA damages in the tumor cells. However, cells have the ability to induce DNA reparation, capable of causing treatment resistance. DNA reparation in non-tumor tissues can also explain the toxicity of cancer treatments. Investigation of DNA repair pathways involved in chemo- or radiation resistance could offer a good strategy for identifying biomarkers or indicators of treatment response. This study will explore the capacity of a comprehensive functional approach that addresses several pathways, based on the use of three innovative patented technologies, to classify the tumor response of HNSCC patients to treatments according to their DNA Repair Enzyme Signature. Our hypothesis is that taking into account various clinical parameters (e.g. patient and tumor characteristics), treatment strategy and measuring the DNA Repair Enzyme Signature would create patients' profiles and optimize their management.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date November 23, 2020
Est. primary completion date November 23, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age over 18 years old; - HNSCC proven on a biopsy, located in the oral cavity or the oropharynx (the tumor must be accessible to a biopsy during an outpatient visit); - Tumor accessible to a biopsy under local anesthesia; - TNM classification: any stage except M1; - Eligible for radiotherapy as a curative treatment; - No surgery planned as exclusive treatment; - Able to comply with the scheduled visits; - Affiliated to or beneficiary of a social security system (or equivalent) ; - Having given written informed consent prior to any procedure related to the study. Exclusion Criteria: - Recurrence or second cancer in a previously irradiated area; - Nasopharyngeal carcinoma; - Tumor requiring general anesthesia to perform the biopsy; - Radiotherapy planned to be provided outside of the investigation center; - Pregnant or lactating woman; - Adult ward of court (under guardianship or trusteeship).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
CHEMRAD assay
CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.

Locations

Country Name City State
France CHU Grenoble - Hôpital Michallon Grenoble
France Centre Léon Bérard Lyon
France Hospices Civils de Lyon - Hôpital de la Croix Rousse Lyon
France Hospices Civils de Lyon Pierre-Bénite

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary DNA Repair Enzyme Signature biomarkers profiles according to intrinsic or treatment-induced radio- or chemo-resistance in different tumor and clinical settings. Results of DNA Repair Enzyme biomarker profiles of tumor cells will be quantified before and during treatment with:
The excision/synthesis assay, as the incorporated fluorescence intensity;
The ODN (Oligonucleotide) assay, as the percentage of cleavage for the DNA target lesions;
The DSB (Double-strand breaks) Assay, as the incorporated fluorescence intensity.
The radio- or chemo-resistance will be defined as disease-free survival, i.e. absence of local or regional recurrence in irradiated tissue seen on CT-scan.
The different tumor and clinical settings will be determined with:
Patient and tumor characteristics, i.e. age, sex, etiological factors (tobacco, alcohol), localization and stage of the tumor, HPV (Human Papilloma Virus) status, p53 status;
Treatment strategy, i.e. all the treatments that will be administered to the patient and their sequence, including International Nonproprietary Name of the drugs and doses of chemo and/or radiotherapy
18 months after the end of the treatments (approximately 24 months after the beginning of the study)
Secondary DNA Repair Enzyme Signature biomarkers profiles according to instrinsic or treatment-induced radio- or chemo-resistance. Results of DNA Repair Enzyme biomarker profiles of tumor cells will be quantified before and during treatment with:
The excision/synthesis assay, as the incorporated fluorescence intensity;
The ODN assay, as the percentage of cleavage for the DNA target lesions;
The DSB Assay, as the incorporated fluorescence intensity. The radio- or chemo-resistance will be defined as disease-free survival, i.e. absence of local or regional recurrence in irradiated tissue measured on the CT-scan performed 4 months after the end of the treatment.
4 months after the end of the treatments (approximately 10 months after the beginning of the study)
Secondary DNA Repair Enzyme Signature biomarkers profiles according to tumor response to treatment Results of DNA Repair Enzyme biomarker profiles of tumor cells will be quantified before and during treatment with:
The excision/synthesis assay, as the incorporated fluorescence intensity;
The ODN assay, as the percentage of cleavage for the DNA target lesions;
The DSB Assay, as the incorporated fluorescence intensity. Global response to treatment measured on the CT-scan according to RECIST criteria, at 4 months after the end of the treatment.
4 months after the end of the treatments (approximately 10 months after the beginning of the study)
Secondary DNA Repair Enzyme Signature biomarkers profiles according to tumor response to treatment Results of DNA Repair Enzyme biomarker profiles of tumor cells will be quantified before and during treatment with:
The excision/synthesis assay, as the incorporated fluorescence intensity;
The ODN assay, as the percentage of cleavage for the DNA target lesions;
The DSB Assay, as the incorporated fluorescence intensity. Global response to treatment measured on the CT-scan according to RECIST criteria, at 18 months, after the end of the treatment.
18 months after the end of the treatments (approximately 24 months after the beginning of the study)
Secondary DNA Repair Enzyme Signature biomarkers profiles according to immediate treatment-induced toxicity Results of DNA Repair Enzyme biomarker profiles of tumor cells will be quantified before and during treatment with:
The excision/synthesis assay, as the incorporated fluorescence intensity;
The ODN assay, as the percentage of cleavage for the DNA target lesions;
The DSB Assay, as the incorporated fluorescence intensity. Treatment-induced adverse events occurring during the treatment.
At the end of the treatments (an average of 6 months after the beginning of the study)
Secondary DNA Repair Enzyme Signature biomarkers profiles of Peripheral Blood Mononuclear Cells (PBMCs). Results of DNA repair enzyme signature of Peripheral Blood Mononuclear Cells quantified before and during treatment with:
The ODN assay, as the percentage of cleavage for the DNA target lesions;
The DSB Assay, as the incorporated fluorescence intensity.
4 months after the end of the treatment (approximately 10 months after the beginning of the study)
Secondary DNA Repair Enzyme Signature biomarkers profiles of Peripheral Blood Mononuclear Cells (PBMCs). Results of DNA repair enzyme signature of Peripheral Blood Mononuclear Cells quantified before and during treatment with:
The ODN assay, as the percentage of cleavage for the DNA target lesions;
The DSB Assay, as the incorporated fluorescence intensity.
18 months after the end of the treatment (approximately 24 months after the beginning of the study)
See also
  Status Clinical Trial Phase
Completed NCT05746780 - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Completed NCT00318890 - Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck Phase 1/Phase 2
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT06010381 - Muscle Energy Technique Versus Maitland Mobilization on Shoulder Pain and Disability N/A
Recruiting NCT06432998 - Perineal Massage in Women With Gynecological Cancer N/A
Terminated NCT01910753 - Physical Activity Program and Nutrition Therapeutic Education During Treatment of Head and Neck Cancer Population N/A
Completed NCT01194466 - Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC) N/A
Recruiting NCT03530033 - Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring N/A
Recruiting NCT05549414 - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System N/A
Recruiting NCT04750434 - PET MRI as a Staging Tool for Head and Neck Cancer
Withdrawn NCT05472506 - Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer Phase 1
Not yet recruiting NCT04261179 - Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer Phase 4
Completed NCT00723463 - Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue Phase 0
Recruiting NCT04673981 - Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA) N/A
Not yet recruiting NCT05946577 - Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
Completed NCT05246891 - Rehabilitation Nursing Program in Otolaryngology
Completed NCT02738268 - Laser Therapy for the Prevention of Radiodermatitis in Head and Neck Patients N/A
Recruiting NCT04722523 - A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Phase 1
Completed NCT03245788 - Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study N/A